Medtronic Spine Sales Down In Fiscal Q3, But Firm Expects A Rebound In 2011
This article was originally published in The Gray Sheet
Executive Summary
Medtronic is looking to turn around its flagging spine business by mid-2011, CEO Bill Hawkins said during the firm's Feb. 23 fiscal third quarter earnings call
You may also be interested in...
CareFusion Aims To Accelerate Infusion Sales Growth Post Baxter Recall
CareFusion expects to grow infusion system sales at a brisk rate in fiscal 2011, in part by capitalizing on Baxter's ongoing infusion pump recall, the firm said during its Aug. 10 earnings call
CareFusion Aims To Accelerate Infusion Sales Growth Post Baxter Recall
CareFusion expects to grow infusion system sales at a brisk rate in fiscal 2011, in part by capitalizing on Baxter's ongoing infusion pump recall, the firm said during its Aug. 10 earnings call
Medtronic Analyst Conference In Brief
60 "major" launches planned for 2011: Medtronic plans to launch 60 "major" new products within the next year, including magnetic-resonance-imaging-safe implants, CEO Bill Hawkins told analysts at a June 7 investor and analyst meeting in New York. He noted Medtronic has 25 PMAs under review at FDA, as well as approximately 30 "major" clinical trials. "I have been with the company for nine years, and I cannot remember a time when our pipeline has been as robust and full," Hawkins said. "We are investing roughly 9[%] to 10% of our sales dollars in organic R&D, which translates into about $1.6 billion.